Obese patients with atrial fibrillation are more efficiently protected from thrombosis under warfarin or xabans compared to non-obese patients; a systematic review and Meta-analysis of six randomized controlled trials

Recommendations about proper anticoagulation in obese patients, body mass index (BMI)  > 30 kg/m2, are not yet clearly defined. Obese patients were included in randomized controlled trials comparing new anticoagulants (NOACs) with warfarin in patients with atrial fibrillation or thromboembolism.

Source: Thrombosis Research - April 23, 2024 Category: Hematology Authors: Lazaros Karatisidis, Konstantinos Zagoridis, Theodoros Mprotsis, Christina Misidou, Aikaterini Pentidou, George Vrachiolias, Zoi Bezirgianidou, Emmanouil Kontomanolis, Emmanouil Spanoudakis Source Type: research